| Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer (NCT05406674) | The Netherlands Cancer Institute | 2022-06-15 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy (NCT04204811) | Memorial Sloan Kettering Cancer Center | 2019-12-16 |
| Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives (NCT04257045) | M.D. Anderson Cancer Center | 2019-08-21 |
| Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF (NCT03604315) | M.D. Anderson Cancer Center | 2018-12-18 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma (NCT06972693) | European Institute of Oncology | 2018-06-12 |
| Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas (NCT02033616) | Aivita Biomedical, Inc. | 2017-11-18 |
| Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 (NCT03296826) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2017-11-08 |
| Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer (NCT03297489) | Roswell Park Cancer Institute | 2017-11-06 |
| Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer (NCT02530606) | Stanford University | 2016-09-01 |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer (NCT02788708) | Floor Backes | 2016-05-27 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (NCT02345265) | National Cancer Institute (NCI) | 2016-05-23 |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (NCT02584478) | Advenchen Laboratories, LLC | 2015-12-01 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery (NCT02315469) | NRG Oncology | 2015-02-10 |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer (NCT02344095) | Seoul National University Hospital | 2014-12-01 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (NCT02166905) | Roswell Park Cancer Institute | 2014-10-10 |
| Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT02118285) | Masonic Cancer Center, University of Minnesota | 2014-07-28 |
| Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT02199171) | University of California, Irvine | 2014-07-01 |
| HOT: HIPEC in Ovarian Cancer as Initial Treatment (NCT02124421) | Mercy Medical Center | 2014-04-01 |
| Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer (NCT02125513) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2014-01-01 |
| (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma (NCT01936974) | Western Regional Medical Center | 2013-09-01 |
| Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? (NCT01611766) | Shanghai Gynecologic Oncology Group | 2012-07-19 |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma (NCT01519869) | Rachel Miller | 2012-03-01 |
| Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma (NCT02328716) | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | 2012-02-01 |
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (NCT01381861) | Tracon Pharmaceuticals Inc. | 2011-07-01 |
| Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT01295489) | Gynecologic Oncology Group | 2011-03-01 |
| Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 (NCT01445275) | Gynecologic Oncology Group | 2011-01-01 |
| EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01118052) | Gynecologic Oncology Group | 2010-11-01 |
| Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer (NCT01139957) | Gynecologic Oncology Group | 2010-06-07 |
| Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy (NCT01709487) | Jules Bordet Institute | 2010-05-01 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648) | National Cancer Institute (NCI) | 2010-04-14 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT01097746) | M.D. Anderson Cancer Center | 2010-04-14 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00989651) | National Cancer Institute (NCI) | 2009-10-28 |
| A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer (NCT01773889) | The University of Texas Health Science Center at San Antonio | 2009-06-01 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00814086) | Gynecologic Oncology Group | 2009-02-01 |
| Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study (NCT00968799) | Cantonal Hospital of St. Gallen | 2008-02-01 |
| Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy (NCT00551265) | Gynecologic Oncology Group | 2007-10-01 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00499252) | Gynecologic Oncology Group | 2007-06-01 |
| A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (NCT00880360) | The University of Texas Health Science Center at San Antonio | 2007-02-01 |
| Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors (NCT00301756) | National Cancer Institute (NCI) | 2006-09-01 |
| Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer (NCT00352300) | Gynecologic Oncology Group | 2006-06-01 |
| Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00066456) | Gynecologic Oncology Group | 2003-09-01 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer (NCT00060359) | Gynecologic Oncology Group | 2003-04-01 |